Drug Trial Radar · NCT03112603
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Jun 29, 2017
Primary completion
May 8, 2020
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Apr 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
Conditions
- Graft-versus-host Disease (GVHD)
Interventions
RuxolitinibDrug
Ruxolitinib twice daily at the protocol-defined starting dose.
Extracorporeal photopheresis (ECP)Drug
Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
Low-dose methotrexate (MTX)Drug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Mycophenolate mofetil (MMF)Drug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)Drug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
InfliximabDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
RituximabDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
PentostatinDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
ImatinibDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
IbrutinibDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 VisitTime frame: Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Locations
191 sites in 31 countries. Site status is shown where the registry gives one.
Incyte Investigative Site
Tucson, Arizona
Incyte Investigative Site
Duarte, California
Incyte Investigative Site
La Jolla, California
Incyte Investigative Site
Los Angeles, California
Incyte Investigative Site
New Haven, Connecticut
Incyte Investigative Site
Wilmington, Delaware
Incyte Investigative Site
Gainesville, Florida
Incyte Investigative Site
Tampa, Florida
Incyte Investigative Site
Chicago, Illinois
Incyte Investigative Site
Chicago, Illinois
Incyte Investigative Site
Chicago, Illinois
Incyte Investigative Site
Maywood, Illinois
Incyte Investigative Site
Indianapolis, Indiana
Incyte Investigative Site
Westwood, Kansas
Incyte Investigative Site
Lexington, Kentucky
Incyte Investigative Site
Boston, Massachusetts
Incyte Investigative Site
Boston, Massachusetts
Incyte Investigative Site
Omaha, Nebraska
Incyte Investigative Site
Hackensack, New Jersey
Incyte Investigative Site
New York, New York
Incyte Investigative Site
New York, New York
Incyte Investigative Site
New York, New York
Incyte Investigative Site
Chapel Hill, North Carolina
Incyte Investigative Site
Durham, North Carolina
Incyte Investigative Site
Winston-Salem, North Carolina
Incyte Investigative Site
Cincinnati, Ohio
Incyte Investigative Site
Cleveland, Ohio
Incyte Investigative Site
Cleveland, Ohio
Incyte Investigative Site
Columbus, Ohio
Incyte Investigative Site
Oklahoma City, Oklahoma
Incyte Investigative Site
Philadelphia, Pennsylvania
Incyte Investigative Site
Pittsburgh, Pennsylvania
Incyte Investigative Site
Pittsburgh, Pennsylvania
Incyte Investigative Site
Nashville, Tennessee
Incyte Investigative Site
Dallas, Texas
Incyte Investigative Site
Houston, Texas
Incyte Investigative Site
Seattle, Washington
Incyte Investigative Site
Milwaukee, Wisconsin
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.